Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by INC Research
Apotex Inc.
Boehringer Ingelheim
Bristol-Myers Squibb
Cipla Ltd.
Gilead Sciences
HEC Pharm
Hetero USA
IPCA Laboratories Ltd.
Janssen R&D Ireland
Merck Sharp & Dohme Corp.
Mylan Laboratories
Prinston Pharma
Ranbaxy Inc.
Roche Pharma AG
Sciegen Pharmaceuticals
Sigmapharm Laboratories
Strides Arcolab Ltd.
Teva Pharmaceuticals USA
ViiV Healthcare (represented by GlaxoSmithKline)
Information provided by (Responsible Party):
INC Research Identifier:
First received: November 27, 2006
Last updated: September 19, 2013
Last verified: September 2013
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2015
  Estimated Primary Completion Date: No date given